Skip to main content

Cimerli (ophthalmic)

Generic name: ranibizumab (ophthalmic) [ RA-ni-BIZ-ue-mab-off-THAL-mik ]
Brand names: Byooviz, Cimerli, Lucentis, Susvimo, Susvimo Implant Kit
Drug class: Anti-angiogenic ophthalmic agents

Medically reviewed by Drugs.com on Oct 31, 2023. Written by Cerner Multum.

What is ranibizumab?

Ranibizumab ophthalmic (for the eyes) is used in adults to treat the "wet form" of age-related macular degeneration. Ranibizumab is also used in adults to treat swelling in the retina caused by diabetes, or a blockage in blood vessels.

Ranibizumab can also be used in adults to treat diabetic retinopathy, and myopia caused by abnormal growth of new blood vessels in the retina.

Ranibizumab may also be used for purposes not listed in this medication guide.

Ranibizumab side effects

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Cimerli may cause serious side effects. Call your doctor at once if you have:

Common side effects of Cimerli may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings

You should not receive ranibizumab if you have swelling, redness, pain inside your eyes, or any type of infection in or around your eyes.

Call your doctor at once if you have sudden vision problems, eye pain, redness, discharge, or watering in your eye, or if your eyes are more sensitive to light.

Before taking this medicine

You should not receive ranibizumab if you are allergic to it, or if you have:

Tell your doctor if you have or have ever had:

It is not known if ranibizumab will harm an unborn baby. Use effective birth control while using ranibizumab and for at least 12 months after your last dose. Tell your doctor if you are pregnant or plan to become pregnant.

Ask a doctor if it is safe to breastfeed while using this medicine.

How is ranibizumab given?

Follow all directions on your prescription label and read all medication guides or instruction sheets.

Ranibizumab injection is administered as an injection into the eye. Your doctor will use a medicine to numb your eye before giving you the injection. You will receive this injection in your doctor's office or other clinical setting.

Ranibizumab eye implant is placed through the white part of the eye by your healthcare provider who will refill your implant once every 6 months.

If you have a ranibizumab eye implant, talk to your doctor if you have an appointment for an MRI (magnetic resonance imaging).

Your eyes will be checked to make sure ranibizumab has not caused any serious side effects.

Call you doctor right away if you notice the eye implant has moved out of place.

Wash your hands first if you have to rub your eyes or touch the area where the eye implant is located.

Syfovre, dexamethasone ophthalmic, triamcinolone ophthalmic, Eylea, Vabysmo, fluocinolone ophthalmic, aflibercept ophthalmic, Lucentis, Izervay, ranibizumab ophthalmic

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your ranibizumab injection.

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid after receiving ranibizumab?

Avoid driving or hazardous activity until the eye shield can be removed and you are able to see clearly.

What other drugs will affect ranibizumab?

Medicine used in the eyes is not likely to be affected by other drugs you use. But many drugs can interact. Tell your doctor about all your current medicines, including prescription and over-the-counter medicines, vitamins, and herbal products.

Does Cimerli interact with my other drugs?

Enter other medications to view a detailed interaction report.

Popular FAQ

What are biosimilar drugs and how do they compare to biologics?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. One example is Amjevita (adalimumab-atto), the first biosimilar approved for Humira (adalimumab) in 2016. Continue reading

More FAQ

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.